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ICD-9 codes are conventionally used to identify pelvic inﬂammatory disease (PID) from administrative data for surveillance
purposes. This approach may include non-PID cases. To reﬁne PID case identiﬁcation among women with ICD-9 codes suggestive
of PID, a case-ﬁnding algorithm was developed using additional variables. Potential PID cases were identiﬁed among women aged
15–44yearsatGroupHealth(GH)andKaiserPermanenteColorado(KPCO)andveriﬁedbymedicalrecordreview.Aclassiﬁcation
and regression tree analysis was used to develop the algorithm at GH; validation occurred at KPCO. The positive predictive value
(PPV) for using ICD-9 codes alone to identify clinical PID cases was 79%. The algorithm identiﬁed PID appropriate treatment
and age 15–25 years as predictors. Algorithm sensitivity (GH = 96.4%; KPCO = 90.3%) and PPV (GH = 86.9%; KPCO = 84.5%)
were high, but speciﬁcity was poor (GH = 45.9%; KPCO = 37.0%). In GH, the algorithm oﬀered a practical alternative to medical
record review to further improve PID case identiﬁcation.
1.Introduction
An estimated 770,000 cases of pelvic inﬂammatory disease
(PID) are diagnosed annually in the United States [1]. PID
comprises infection and inﬂammation of the uterus, fallop-
ian tubes, ovaries, and other adjacent tissue and has multiple
infectiousetiologies, manyof whichhavebeen demonstrated
to be sexually transmitted, including Chlamydia trachomatis
[2]. C. trachomatis has been isolated in approximately one-
quarter of patients with a symptomatic PID diagnosis [3].
PID of any etiology may lead to further adverse out-
comes, including tubal-factor infertility, ectopic pregnancy,
and chronic pelvic pain [2]; about 10%–20% of PID cases
are associated with infertility and ectopic pregnancy [3].
The speciﬁc contribution of chlamydia and other infec-
tions associated with PID (e.g., Neisseria gonorrhoeae and
Mycoplasma genitalium) to each of these adverse outcomes
is unknown [4, 5]. However, among infertile couples using
assisted reproductive therapy, 10–20% are diagnosed with
tubal infertility [6, 7]. In an eﬀort to prevent PID and sub-
sequent infertility, chlamydia screening is recommended for
all sexually active women aged <25 years [8, 9]. Prior studies
have suggested that screening can reduce the risk of PID de-
velopment by up to 50% [10, 11].
While monitoring trends in PID is a critical compo-
nent to quantifying the public health burden of PID and
evaluating the impact of chlamydia prevention eﬀorts, PID
surveillance is challenging. In the absence of a laboratory-
based case deﬁnition, PID is diagnosed on the basis of
clinical signs and symptoms [12]. The Centers for Disease
Control and Prevention (CDC) recommends empiric treat-
ment for PID when young women have lower abdominal
pain with no other clear cause, accompanied by either2 Infectious Diseases in Obstetrics and Gynecology
uterine or adnexal or cervical motion tenderness [8]. Thus,
the clinical diagnosis lacks speciﬁcity. The “gold standard”
for diagnosing tubal infection is laparoscopy, an invasive
procedure that is rarely performed in clinical practice [13].
To identify PID cases for research and surveillance purposes,
medical record review provides the best method of verifying
a clinical diagnosis of PID. In lieu of medical record reviews,
ICD-9 codes have been used to identify PID cases from
administrative data. A clinical diagnosis of PID may be
represented by several ICD-9 codes. The most commonly
referenced ICD-9 code, 614.9 (female pelvic inﬂammatory
disease not otherwise speciﬁed) has a positive predictive
value (PPV) of only 18.1% for the PID surveillance case
deﬁnition, a substantially stricter deﬁnition than the clinical
deﬁnition used for empiric treatment [14]. When coupled
with a positive chlamydia test, the PPV increases to 56%;
however, laboratory test results are frequently unavailable in
the administrative datasets used to examine PID rates and
trends. Information is lacking on the PPV of the multiple
I C D - 9c o d e sc u r r e n t l yi nu s ef o rs u r v e i l l a n c eo fa c u t eP I D .
Potential PID cases identiﬁed from administrative data
using ICD-9 codes include some women without PID. To
further reﬁne identiﬁcation of clinically diagnosed PID in
the subset of women with an ICD-9 code suggestive of PID,
medical record review is preferable but is costly. Applying a
PID case-ﬁnding algorithm based on additional administra-
tive data to potential PID cases identiﬁed from ICD-9 codes
m a yb em o r ep r a c t i c a la n da l l o wf o rm o r ea c c u r a t eb u r d e n
and trend ascertainment for PID surveillance activities. The
purpose of this analysis was twofold: (1) to determine the
PPV of using ICD-9 codes alone to identify PID and (2) to
develop a PID case-ﬁnding algorithm using administrative
dataelementstoeasilyidentifyPIDcasesamongwomenwith
PID-related ICD-9 diagnostic codes.
2.MaterialsandMethods
Datafromtwomixedmodelhealthcareorganizations,Group
Health Cooperative (GH, Seattle, Wash, USA) and Kaiser
Permanente Colorado (KPCO, Denver, CO), were used
in this analysis. In 2006, approximately 125,000 women
between the ages of 15 and 44 years were enrolled in GH,
and about 116,000 women of the same ages were enrolled
in KPCO. Both organizations maintain extensive automated
administrative and clinical data including enrollment infor-
mation, demographics, health care utilization, diagnoses,
procedures, laboratory tests, and pharmacy records on each
enrollee.
2.1. Data Collection. A set of 14 ICD-9 codes used in
other epidemiologic evaluations of PID was used to identify
women with potential PID cases in the GH administrative
database (Table 1)[ 1, 15]. Only codes for PID not identiﬁed
as chronic were considered, since these cases may be more
likelytorepresentPIDcasesassociatedwithinfectiouscauses
such as chlamydia that could be prevented by screening
eﬀorts. PID diagnoses that occurred within 60 days of each
other were considered the same PID episode. Using GH data
from 2003 to 2007, there were 2,764 total potential PID
Table 1: ICD-9 codes commonly utilized to identify possible acute
pelvic inﬂammatory disease (PID) and code distribution among
potential PID cases sampled from Group Health Cooperative.




098.10-Acute GC upper GU tract, site
unspeciﬁed
098.16-Acute GC endometritis
098.17-Acute GC salpingitis 5 (1.3)
098.19-Acute GC upper GU tract, other site
098.86-Acute GC peritonitis
099.56-Acute CT peritonitis 0 (0.0)
614.0-Acute salpingo-oophoritis
614.5-Acute or unspeciﬁed pelvic peritonitis 8 (2.0)
614.8-Other speciﬁed inﬂammatory disease,
female pelvic organs
614.2-Salpingitis/oophoritis, not acute or
chronic 22 (5.6)
614.3-Acute parametritis/PID 53 (13.5)
614.9-Unspeciﬁed inﬂammatory disease, female
pelvic organs 252 (64.1)
615.0-Inﬂammatory disease of uterus, except
cervix 15 (3.8)
615.9-Unspeciﬁed inﬂammatory disease of
uterus 80 (20.4)
GC: gonorrhea, GU: genitourinary, CT: chlamydia.
∗A single potential PID case may include multiple ICD-9 codes. 393 total
potentialPIDcaseswereidentiﬁed,andatotalof435ICD-9codeswereused.
cases among women aged 15 to 44 years. During this time
period, PID rates declined slightly from 568 cases/100,000
person-years to 473/100,000; these data have been described
in another publication [16]. From the 2,764 total potential
cases, a sample of 393 potential cases was randomly selected
for medical record review to determine if the clinical
diagnosis was PID. If a woman had multiple PID diagnoses
from 2003 to 2007, only the ﬁrst PID episode was included in
the sample. The distribution of ICD-9 codes associated with
the 393 potential cases is shown in Table 1; multiple ICD-9
codes could have been selected for the visit associated with
each potential PID case.
Determination of the actual PID case status (i.e., clinical
diagnosis) was made by reviewing electronic medical records
using a structured chart review instrument. Potential PID
cases were conﬁrmed as being clinician-diagnosed cases or
not based on explicit clinician documentation of PID used in
the context of diagnosis during the visit (e.g., “PID,” “pelvic
inﬂammatory disease,” “pelvic infection,” “salpingitis,” etc.);
PID documentation used for patient evaluation (e.g., “rule-
out PID”) was not considered. The determination of clinical
PID status was made regardless of the clinical signs or
symptoms indicated to support such a diagnosis. Cases
where the clinical status was uncertain were further reviewed
by a study team member (DS).Infectious Diseases in Obstetrics and Gynecology 3
Table 2: Results from medical record reviews to assess PID cases status at Group Health Cooperative (GH) and Kaiser Permanente Colorado
(KPCO).
PID diagnosis based on medical record review (%) Total
PID Not PID Uncertain No information
GH development dataset 275 (70.0) 74 (18.8) 6 (1.5) 38 (9.7) 393
KPCO validation dataset 349 (69.8) 92 (18.4) 5 (1.0) 54 (10.8) 500
PID: pelvic inﬂammatory disease.
In addition to ICD-9 diagnosis codes for PID shown in
Table 1, other variables potentially associated with PID were
extracted from the GH administrative data to be evaluated
as potential predictors in the development of the PID case-
ﬁndingalgorithm.Theseincludedageatdiagnosis,treatment
for PID, inpatient admission, whether chlamydia testing was
conducted, and other diagnoses occurring 7 days prior to
the ﬁrst PID diagnosis through 7 days after the last PID
diagnosis in an episode. These other possible diagnoses
were deﬁned by ICD-9 codes and included appendicitis,
ovariancysts,ectopicpregnancy,pyelonephritis,pancreatitis,
leiomyoma, and endometriosis. Treatment appropriate for
PID was deﬁned as levoﬂoxacin (500mg orally once per day
for 14 days) or oﬂoxacin (400mg orally twice per day for
14 days) based on 2006 recommended PID treatment [12];
other possible antimicrobial regimens for PID treatment
were also included.
Administrative and medical record data from KPCO
were used as an external validation dataset to evaluate the
performance of the PID case-ﬁnding algorithm in another
setting. In the KPCO administrative data from 2003 to 2008,
2,685 potential PID cases among women aged 15 to 44
years were identiﬁed using the same ICD-9 codes (Table 1).
Of these, 500 were randomly selected for medical record
review to determine the clinical PID case status. The same
structured chart review instrument that was used in the GH
development dataset was used for the medical record review
at KPCO. All study procedures received human subjects
review and approval at each institution (GH and KPCO).
2.2. Statistical Analysis. A classiﬁcation and regression tree
(CART) analysis was performed to develop a PID case-
ﬁnding algorithm using the GH dataset. CART has previ-
ously been used to improve ectopic pregnancy case ﬁnding
and to identify diabetes cases [17, 18]. The algorithm
goal in this analysis was to identify additional widely-
availablevariablesfromadministrativedatathatwouldaidin
predicting clinical PID cases as deﬁned by the medical record
review. CART is a nonparametric, binary recursive parti-
tioning method that builds a decision tree or a classiﬁcation
algorithm by splitting data into two groups at each branch
(or “node”) [19]. Important predictors are hierarchically
identiﬁed, and potential cases are classiﬁed as PID cases
or not at each node. In this analysis, potential predictors
considered included ICD-9 codes (Table 1), age at diagnosis,
whether treatment appropriate for PID was given, inpatient
admission, whether chlamydia testing was conducted, and
other concurrent diagnoses (described above). This process
is repeated multiple times until the optimal tree is built.
At each branch, data are optimally split to maximize the
diﬀerentiation of observations based on the dependent var-
iable; in this case, the dependent variable was a conﬁrmed
clinical PID diagnosis (yes/no) from medical record review.
The PID case-ﬁnding algorithm developed using GH
data was then applied to the KPCO data. Algorithm per-
formance was assessed by comparing the PID case status
predicted by the algorithm to the PID case status determined
by medical record review in each sample dataset (GH and
KPCO). Summary statistics evaluating the performance of
the algorithm were calculated in the sample population of
women with ICD-9 codes related to PID; the medical record
review results were assumed to be the truth. Sensitivity was
deﬁned as the proportion of PID cases correctly classiﬁed by
ICD-9 code and conﬁrmed by medical record review as PID
cases that were identiﬁed as PID by the algorithm. Speciﬁcity
was the proportion of PID cases identiﬁed by ICD-9 code
but determined to not be PID that were correctly classiﬁed as
not PID by the algorithm. Negative predictive value (NPV)
was calculated as the proportion of potential cases classiﬁed
by the algorithm as not PID that were identiﬁed by ICD-
9 code and found not to be PID by medical record review.
Positivepredictivevalue(PPV)wasdeﬁnedastheproportion
of algorithm-classiﬁed PID cases that were conﬁrmed to
be PID by medical record review. The PPV of selecting
PID cases using ICD-9 codes alone was also calculated. The
overall misclassiﬁcation proportion was calculated as the
proportion of potential PID cases incorrectly classiﬁed by
the algorithm when compared to the medical record review
ﬁndings. The 95% conﬁdence intervals (CIs) based on the
binomial distribution were calculated for all performance
measures.
Analyses were conducted using SAS version 9.1.2 (SAS
Institute Inc., Cary, NC), R (R Foundation for Statistical
Computing, Vienna, Austria), and OpenEpi [20, 21]. The
CARTanalysiswasperformedusing“rpart”intheRpackage.
3. Results
Among the sample of 393 potential PID cases identiﬁed at
GHusingICD-9codesalone,275(70.0%)wereconﬁrmedto
be clinical PID based on medical record review; 74 (18.8%)
were not PID; 6 (1.5%) were of uncertain case status; 38
(9.7%) had no information available regarding the visit
where the PID ICD-9 code was recorded (Table 2). Of the
sample of 500 potential KPCO PID cases, 349 (69.8%) were
conﬁrmedtobePID,92(18.4%)werenotPID,5(1.0%)were
uncertain, and 54 (10.8%) had no information available on
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349∗ potential PID cases
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Figure 1: Case-ﬁnding algorithm developed using automated administrative data from Group Health Cooperative to reﬁne identiﬁcation
of PID among a sample of women with ICD-9 codes suggestive of PID. PID: pelvic inﬂammatory disease. ∗Of 393 potential PID cases with
ICD-9 codes associated with PID, 44 were not included due to uncertainty of PID case status after medical record review.
Of the 14 ICD-9 codes used to identify potential PID
cases from GH, 614.9 was the most common, associated with
64.1% of the 393 potential cases (Table 1). The majority of
visits where a potential PID case was identiﬁed had only one
ICD-9 selected (92.4%), 5.9% had two codes, and 1.8% had
three or more. In GH, 68.0% of the 275 conﬁrmed PID cases
hadanICD-9codeof614.9.Ofthe500potentialPIDcasesat
KPCO, 50.4% were coded with the 614.9 ICD-9 code; 48.4%
of the 441 conﬁrmed PID cases had the 614.9 code recorded.
When using ICD-9 codes alone to identify PID cases at
GH, the PPV was 78.8% (95% CI: 74.1–83.0%). The results
weresimilarforKPCO,wherethePPVforusingICD-9codes
was 79.1% (95% CI: 75.0–82.8).
The PID case-ﬁnding algorithm is shown in Figure 1.O f
the 393 potential PID cases at GH, the 44 with uncertain
case status or no information available were excluded.
Thus, 349 potential PID cases were used to develop the
algorithm. Two predictors of clinical PID were identiﬁed
by the algorithm. The strongest predictor identiﬁed was the
presence of treatment appropriate for PID. The algorithm
classiﬁed 278 potential cases with documented treatment
in administrative data as PID cases, of which 249 (89.6%)
were conﬁrmed as clinically diagnosed PID. Among those
women with no PID treatment recorded, younger age was
foundtobethemostimportantpredictor.Speciﬁcally,young
women between 15–25 years of age who had not received
PID treatment were classiﬁed by the algorithm as PID cases.
Among 27 such women, 16 (59.3%) were conﬁrmed PID
cases.Among44womenwhohadnoPIDtreatmentandwere
aged 26–44 years, 34 (77.3%) were correctly classiﬁed by the
algorithm as not having PID. No speciﬁc ICD-9 code was a
stronger predictor than PID treatment and age.
The summary statistics of the algorithm performance
using GH and KPCO sample data are shown in Table 3.A t
GH, algorithm sensitivity was 96.4% (95% CI: 93.4–98.2%),
speciﬁcitywas45.9%(95%CI:34.3–57.9%),NPVwas77.3%
(95% CI: 62.2–88.5%), and PPV was 86.9% (95% CI: 82.9–
90.5%). Using the algorithm, 14.3% of potential PID cases in
the sample population of women with ICD-9 codes related
to PID were misclassiﬁed. When applied to the validation
dataset from KPCO, algorithm sensitivity was 90.3% (95%
CI: 86.7%–93.2%), speciﬁcity was 37.0% (95% CI: 27.1%–
47.7%), NPV was 50.0% (95% CI: 37.6%–62.4%), and PPV
was 84.5% (95% CI: 80.4–88.0); 20.9% of the potential cases
were misclassiﬁed.
The distribution of the two predictors included in the
algorithm was similar for PID treatment between GH and
KPCO potential PID cases, but diﬀerent for age at PID
diagnosis. In GH, 90.6% (249/275) of conﬁrmed PID cases
had documented treatment appropriate for PID, compared
to 39.2% (29/74) of cases found not to be PID. Likewise,
in KPCO, 84.0% (293/349) of conﬁrmed PID cases had
documented appropriate antimicrobial treatment, compared
to 38.0% (35/92) of non-PID cases. When examining age
at diagnosis in GH, 49.1% (135/275) of conﬁrmed PID
cases were <26 years, compared to 28.4% (21/74) of cases
conﬁrmed by medical record review to not be PID. However,
in KPCO women aged <26 years accounted for 38.1%
(133/349) of conﬁrmedPID casesand 41.3%(38/92) of cases
that were not PID.Infectious Diseases in Obstetrics and Gynecology 5
Table 3: Performance statistics for PID case identiﬁcation using an algorithm applied to sample administrative data from women with an
ICD-9 code∗ related to PID.






Not PID 34 40 74
PID 10 265 275
Total 44 305 349






Not PID 34 58 92
PID 34 315 349
Total 68 373 441
(c)
Performance Statistics (95% CI) GH development dataset KPCO validation dataset
PID case identiﬁcation using
ICD-9 codes∗ alone
PPV 78.8% (74.1–83.0%) 79.1% (75.0–82.8%)
PID case identiﬁcation using
algorithm
Sensitivity 96.4% (93.4–98.2%) 90.3% (86.7–93.2%)
Speciﬁcity 45.9% (34.3–57.9%) 37.0% (27.1–47.7%)
PPV 86.9% (82.6–90.5%) 84.5% (80.4–88.0%)
NPV 77.3% (62.2–88.5%) 50.0% (37.6–62.4%)
Proportion of potential cases
misclassiﬁed 14.3% (10.8–18.5%) 20.9% (17.2–25.0%)
∗ICD-9 codes shown in Table 1. Only potential cases with complete chart-review information are included.
GH: Group Health, KPCO: Kaiser Permanente Colorado, PID: pelvic inﬂammatory disease, CI: conﬁdence interval, PPV: positive predictive value, NPV:
negative predictive value.
4. Discussion
One of the primary goals in STD prevention is to reduce the
burden of STD-associated infertility. Monitoring trends in
PID, an intermediate adverse outcome between STD acqui-
sition and the development of infertility, may help identify
progress in STD prevention. However, surveillance of PID,
which often relies on case identiﬁcation from administrative
data sources, has been historically diﬃcult.
To identify clinical diagnoses of PID from medical
records data for surveillance and research purposes, admin-
istrators and researchers have traditionally relied solely on
ICD-9 diagnostic codes. In this study, using a standard set
of ICD-9 codes to identify potential PID cases, a simple
approach, the PPV relative to medical record review, was
fairly high, about 79% at both sites. However, use of ICD-
9 codes has limitations, including a lack of speciﬁcity [14],
nonstandard application (especially when multiple codes
may be used to designate a condition), and varying usage
across individuals and healthcare sites in selecting which
ICD-9 codes to use.
The algorithm developed in this analysis incorporated
additional automated data elements as a practical alternative
to medical record review to improve PID case ﬁnding
among the subset of women with PID-related ICD-9 codes.
Algorithm sensitivity (GH = 96.4%; KPCO = 90.3%) and
PPV (GH = 86.9%; KPCO = 84.5%) were high at both sites,
but higher at the site where the algorithm was developed
(GH). However, speciﬁcity and NPV were low at both sites,
although, again, performance was better at the algorithm
development site. In GH, the proportion of potential PID
cases misclassiﬁed by the algorithm was 14.3%; at KPCO, the
proportion of cases that were misclassiﬁed using algorithm
was20.9%.Thus,thealgorithmdevelopedusingGHdatadid
not appear to perform as well in this second site. However,
when using ICD-9 codes alone to identify potential PID
cases, the PPV was 79%; the PPV increased to 85% in KPCO
and 87% in GH when the algorithm was applied. Given
the challenges in case identiﬁcation and PID surveillance,
small improvements such as the availability of a case-ﬁnding
algorithm oﬀer opportunities to move beyond the practice
of identifying PID cases based only on ICD-9 codes. As this6 Infectious Diseases in Obstetrics and Gynecology
study indicates, the extent of such value may be speciﬁc to
the population under evaluation.
Currently, due to widespread data limitations, public
health professionals must rely primarily on ecologic com-
parisons of STD incidence trends, PID diagnosis trends, and
concurrent sexually transmitted disease (STD) prevention
activities to evaluate programmatic impact. As data sys-
tems improve, ascertainment of STD-speciﬁc PID diagnoses
may be possible with better automated linkages between
laboratory data, clinical data, and inclusion of additional
administrative data. The expanded use of electronic medical
records will likely oﬀer opportunities to further enhance
surveillance of STD-associated PID. The identiﬁcation of
possible methods to improve PID case ﬁnding will be a
contributing factor.
This analysis has several limitations. Due to budget and
time constraints, only a limited number of medical record
abstractions were possible and thus, the algorithm developed
may not be robust. A larger sample may have resulted in
ad i ﬀerent algorithm. A random sample of potential PID
cases based on ICD-9 diagnostic codes was selected in both
sites, and the data used to develop and validate the algorithm
should be generally representative of the entire population
of potential PID cases with an associated ICD-9 code in GH
andKPCOduringthestudyperiod.Inthisanalysis,potential
PID cases were identiﬁed using ICD-9 codes; ICD-9 codes
may not be applied consistently across healthcare settings.
No information on the population with PID not identiﬁed
by ICD-9 codes (false negatives) was available; therefore,
the sensitivity, speciﬁcity, and negative predictive value of
using ICD-9 codes alone to identify clinically diagnosed
PID cases could not be determined. Lastly, the algorithm
performance statistics did not include women whose clin-
ical PID status was missing or unable to be determined;
fortunately, this ﬁnding occurred in a fairly low proportion
of potential cases. While the algorithm would classify these
cases as PID or not, the performance of the algorithm
could not be assessed without medical record review
information.
Strengths of this analysis include an evaluation of the
group of ICD-9 codes currently in use to identify PID in
administrative data. This study is one of the ﬁrst to examine
how these codes perform relative to clinical PID case detec-
tion as deﬁned by medical record review. The utilization of
CART methodology represents another strength. This strat-
egy allowed for a comprehensive evaluation of additional
available automated predictors of clinically diagnosed PID
cases and all possible value splits of those predictors without
the necessity of making assumptions about underlying var-
iable distributions (a nonparametric approach). Interpreta-
tion of the CART ﬁndings is straightforward and was eas-
ily applied to another external setting (KPCO) after initial
algorithm development to allow for an assessment of algo-
rithm robustness.
5. Conclusions
Monitoring PID is important in assessing STD prevention
and control eﬀorts, particularly prevention of chlamydia and
gonorrhea. The approaches utilized in this analysis may help
improve PID surveillance eﬀorts. While the challenge of
diagnosing PID remains, results in the two study settings
show that the PPV of using ICD-9 codes alone to predict a
clinical PID diagnosis was quite high. At GH, the PID case-
ﬁnding algorithm also oﬀers a practical alternative to further
reﬁne PID case identiﬁcation among the group of women
with ICD-9 codes suggestive of PID. Further exploration
of case-ﬁndings predictors in a larger sample may result
in a more robust and generalizable algorithm. Research on
additional novel approaches to identify clinical PID cases
from administrative data should continue.
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